Brenig Therapeutics to Showcase BT-267 Phase 1 Findings at AAN 2026

Brenig Therapeutics to Present Breakthrough Phase 1 Data

Brenig Therapeutics Inc., a prominent biotech company, is ready to reveal significant findings from its ongoing Phase 1 study on BT-267 at the upcoming American Academy of Neurology (AAN) Annual Meeting scheduled from April 18 to 22, 2026, in Chicago, Illinois. This meeting is an esteemed event in the neurology field, attracting numerous medical professionals and researchers.

About BT-267 and the Phase 1 Study

BT-267 is a selective, brain-penetrant small molecule therapy designed specifically for neurodegenerative diseases, particularly aiming at Parkinson’s disease through its role as a potent LRRK2 inhibitor. During the presentation, Chief Medical Officer Dr. Tien Dam will unveil the poster titled "Phase One Study of BT-267, A Potent, Selective, Brain-penetrant, and Oral Small Molecule Inhibitor of LRRK2." This presentation will take place on April 21, from 11:45 AM to 12:45 PM CDT, at McCormick Place West, Hall F.

The poster will contain crucial updated information on the pharmacokinetic profile of BT-267, its target engagement, as well as safety and tolerability assessments from the study involving healthy volunteers. Dr. Megan McGill, CEO of Brenig Therapeutics, expressed enthusiasm about sharing this impactful new clinical data, highlighting BT-267's potential as a leading compound in neurodegenerative treatment landscapes.

The Clinical Significance of BT-267

The data set to be presented at AAN represents a vital step in validating the efficacy and safety of BT-267. The significance of this study lies in its potential to position BT-267 as a leading candidate in treating Parkinson’s disease. Such advancements are crucial considering the increasing prevalence of neurodegenerative disorders globally. Dr. McGill noted, "These data continue to support the potential of BT-267 as a highly brain-penetrant and selective LRRK2 inhibitor, with characteristics that may enable best-in-class positioning in Parkinson's disease and related neurodegenerative conditions."

Further Developments at Brenig

In addition to the presentation of BT-267, Brenig will also discuss BT-409, another of its innovative therapies, which is an NLRP3 inhibitor currently in a Phase 1 dose escalation study. Early reports suggest that BT-409 has been well tolerated among participants, showcasing the promising nature of Brenig’s projects.

Brenig Therapeutics aims to develop ground-breaking therapies that penetrate the brain barrier effectively, ensuring optimal treatment outcomes for patients with central nervous system disorders. By leveraging advanced computational chemistry and multiparametric optimization strategies, the company is committed to developing unique and efficient alternatives in the field of medicinal treatments.

Conclusion

As Brenig Therapeutics prepares to present at one of the world’s largest neurology conferences, the data from this Phase 1 study of BT-267 not only marks a significant milestone for Brenig but potentially holds substantial implications for the treatment of neurodegenerative diseases in the future. The AAN 2026 Annual Meeting will serve as an excellent platform for the presentation of these critical findings, furthering the conversation regarding advancements in neurology and therapeutic innovations.

This showcase could signal a new era for treatments in the field, paving the way for enhanced understanding and management of complex neurological conditions. As interested parties gather in Chicago, the unfolding discussions centered around BT-267 and its innovative approach will inevitably shape the roadmap ahead in neuroscience.

For more information regarding the presentation or details about BT-267 and BT-409, please refer to Brenig Therapeutics' official communications during the conference.